Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Bispecific small molecule-antibody conjugate targeting prostate cancer.

Kim CH, Axup JY, Lawson BR, Yun H, Tardif V, Choi SH, Zhou Q, Dubrovska A, Biroc SL, Marsden R, Pinstaff J, Smider VV, Schultz PG.

Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17796-801. doi: 10.1073/pnas.1316026110. Epub 2013 Oct 14.

2.

A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.

Bühler P, Wolf P, Gierschner D, Schaber I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U.

Cancer Immunol Immunother. 2008 Jan;57(1):43-52. Epub 2007 Jun 20.

3.

Re: bispecific small molecule-antibody conjugate targeting prostate cancer.

Atala A.

J Urol. 2014 Jun;191(6):1927-8. doi: 10.1016/j.juro.2014.03.011. Epub 2014 Mar 18. No abstract available.

PMID:
25280327
4.

A novel bispecific antibody, S-Fab, induces potent cancer cell killing.

Li L, He P, Zhou C, Jing L, Dong B, Chen S, Zhang N, Liu Y, Miao J, Wang Z, Li Q.

J Immunother. 2015 Nov-Dec;38(9):350-6. doi: 10.1097/CJI.0000000000000099.

PMID:
26448579
5.

Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.

Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsässer-Beile U.

Anticancer Res. 2000 May-Jun;20(3A):1551-5.

PMID:
10928069
6.

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids.

Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin K, Lu Y, Tran H, Seller AJ, Biroc SL, Szydlik A, Pinkstaff JK, Tian F, Sinha SC, Felding-Habermann B, Smider VV, Schultz PG.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16101-6. doi: 10.1073/pnas.1211023109. Epub 2012 Sep 17.

7.

A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.

Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmüller G, Dörken B, Bargou RC.

Blood. 2000 Mar 15;95(6):2098-103.

8.

Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates.

Patil V, Gada K, Panwar R, Varvarigou A, Majewski S, Weisenberger A, Ferris C, Tekabe Y, Khaw BA.

Eur J Nucl Med Mol Imaging. 2012 May;39(5):824-39. doi: 10.1007/s00259-011-2050-3.

PMID:
22302089
9.

[Biologic activity of bispecific single chain antibody against human gamma-seminoprotein and CD3 molecule].

Wang D, Wang H, Wu GJ, Wu WZ, Yang SL, Lin WH, Tan JM.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006 Jul;22(4):500-3. Chinese.

PMID:
16806016
10.

Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.

Rodrigues ML, Shalaby MR, Werther W, Presta L, Carter P.

Int J Cancer Suppl. 1992;7:45-50.

PMID:
1428403
12.

Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.

Rozan C, Cornillon A, Pétiard C, Chartier M, Behar G, Boix C, Kerfelec B, Robert B, Pèlegrin A, Chames P, Teillaud JL, Baty D.

Mol Cancer Ther. 2013 Aug;12(8):1481-91. doi: 10.1158/1535-7163.MCT-12-1012. Epub 2013 Jun 11.

14.
15.

A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells.

Yamamoto K, Trad A, Baumgart A, Hüske L, Lorenzen I, Chalaris A, Grötzinger J, Dechow T, Scheller J, Rose-John S.

Biochem J. 2012 Jul 1;445(1):135-44. doi: 10.1042/BJ20120433.

PMID:
22509934
16.

Recruiting cytotoxic T cells to folate-receptor-positive cancer cells.

Kularatne SA, Deshmukh V, Gymnopoulos M, Biroc SL, Xia J, Srinagesh S, Sun Y, Zou N, Shimazu M, Pinkstaff J, Ensari S, Knudsen N, Manibusan A, Axup JY, Kim CH, Smider VV, Javahishvili T, Schultz PG.

Angew Chem Int Ed Engl. 2013 Nov 11;52(46):12101-4. doi: 10.1002/anie.201306866. Epub 2013 Sep 25. No abstract available.

17.

Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.

Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P, Kiener PA.

Cancer Res. 2007 Apr 15;67(8):3927-35.

18.

[The enhancement of cytolytic activity in lymphokine activated killer cells using bispecific F(ab')2].

Azuma A.

Nihon Ika Daigaku Zasshi. 1991 Dec;58(6):663-72. Japanese.

PMID:
1663120
19.

Immunotherapy with bispecific antibodies.

Thielemans KM.

Verh K Acad Geneeskd Belg. 1995;57(3):229-47; discussion 247-8.

PMID:
7483816
20.

[Study on p53 tetramerization domain in improving functional affinity and biological activity of antibody].

Wang D, Wu GJ, Tan JM, Wang H.

Zhonghua Yi Xue Za Zhi. 2005 Feb 23;85(7):479-82. Chinese.

PMID:
15854555
Items per page

Supplemental Content

Write to the Help Desk